the foundation for liver research
the foundation for liver research Company Information
Company Number
07156633
Next Accounts
6 days late
Shareholders
-
Group Structure
View All
Industry
Research and experimental development on biotechnology
Registered Address
111 coldharbour lane, london, SE5 9NT
Website
http://liver-research.org.ukthe foundation for liver research Estimated Valuation
Pomanda estimates the enterprise value of THE FOUNDATION FOR LIVER RESEARCH at £4.2m based on a Turnover of £3m and 1.39x industry multiple (adjusted for size and gross margin).
the foundation for liver research Estimated Valuation
Pomanda estimates the enterprise value of THE FOUNDATION FOR LIVER RESEARCH at £0 based on an EBITDA of £-141.9k and a 5.49x industry multiple (adjusted for size and gross margin).
the foundation for liver research Estimated Valuation
Pomanda estimates the enterprise value of THE FOUNDATION FOR LIVER RESEARCH at £91.1m based on Net Assets of £50.9m and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
The Foundation For Liver Research Overview
The Foundation For Liver Research is a live company located in london, SE5 9NT with a Companies House number of 07156633. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in February 2010, it's largest shareholder is unknown. The Foundation For Liver Research is a established, small sized company, Pomanda has estimated its turnover at £3m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
The Foundation For Liver Research Health Check
Pomanda's financial health check has awarded The Foundation For Liver Research a 4 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 4 areas for improvement. Company Health Check FAQs
2 Strong
5 Regular
4 Weak
Size
annual sales of £3m, make it in line with the average company (£3.1m)
£3m - The Foundation For Liver Research
£3.1m - Industry AVG
Growth
3 year (CAGR) sales growth of -3%, show it is growing at a slower rate (12.5%)
-3% - The Foundation For Liver Research
12.5% - Industry AVG
Production
with a gross margin of 54.7%, this company has a comparable cost of product (54.7%)
54.7% - The Foundation For Liver Research
54.7% - Industry AVG
Profitability
an operating margin of -14.7% make it less profitable than the average company (-2.1%)
-14.7% - The Foundation For Liver Research
-2.1% - Industry AVG
Employees
with 23 employees, this is below the industry average (43)
23 - The Foundation For Liver Research
43 - Industry AVG
Pay Structure
on an average salary of £70.2k, the company has an equivalent pay structure (£75.1k)
£70.2k - The Foundation For Liver Research
£75.1k - Industry AVG
Efficiency
resulting in sales per employee of £131.1k, this is equally as efficient (£127.1k)
£131.1k - The Foundation For Liver Research
£127.1k - Industry AVG
Debtor Days
it gets paid by customers after 53 days, this is near the average (56 days)
53 days - The Foundation For Liver Research
56 days - Industry AVG
Creditor Days
its suppliers are paid after 23 days, this is quicker than average (70 days)
23 days - The Foundation For Liver Research
70 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - The Foundation For Liver Research
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 192 weeks, this is more cash available to meet short term requirements (30 weeks)
192 weeks - The Foundation For Liver Research
30 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 2%, this is a lower level of debt than the average (54.8%)
2% - The Foundation For Liver Research
54.8% - Industry AVG
THE FOUNDATION FOR LIVER RESEARCH financials
The Foundation For Liver Research's latest turnover from June 2023 is £3 million and the company has net assets of £50.9 million. According to their latest financial statements, The Foundation For Liver Research has 23 employees and maintains cash reserves of £3.8 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3,015,792 | 2,778,766 | 2,822,721 | 3,303,214 | 3,519,161 | 3,187,522 | 4,031,373 | 2,249,892 | 2,208,539 | 2,646,289 | 2,029,066 | 4,915,820 | 1,358,532 | 2,376,234 |
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | ||||||||||||||
| Interest Payable | ||||||||||||||
| Interest Receivable | ||||||||||||||
| Pre-Tax Profit | -234,028 | -58,651 | 181,857 | 618,208 | 993,038 | 844,672 | 2,308,154 | 492,661 | 428,753 | 797,066 | 197,912 | 3,211,659 | -53,523 | 663,317 |
| Tax | ||||||||||||||
| Profit After Tax | -234,028 | -58,651 | 181,857 | 618,208 | 993,038 | 844,672 | 2,308,154 | 492,661 | 428,753 | 797,066 | 197,912 | 3,211,659 | -53,523 | 663,317 |
| Dividends Paid | ||||||||||||||
| Retained Profit | -234,028 | -58,651 | 181,857 | 618,208 | 993,038 | 844,672 | 2,308,154 | 492,661 | 428,753 | 797,066 | 197,912 | 3,211,659 | -53,523 | 663,317 |
| Employee Costs | 1,614,956 | 1,385,904 | 1,343,184 | 1,405,136 | 1,319,027 | 1,253,706 | 985,949 | 994,600 | 1,060,339 | 1,103,399 | 1,050,779 | 928,633 | 617,071 | |
| Number Of Employees | 23 | 21 | 21 | 21 | 21 | 20 | 17 | 20 | 19 | 18 | 17 | 11 | ||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 6,545,655 | 6,784,425 | 5,522,751 | 5,815,159 | 5,880,011 | 6,038,086 | 5,979,175 | 5,094,786 | 3,873,610 | 4,448,324 | 2,944,255 | 3,087,221 | 2,725,333 | 2,570,355 |
| Intangible Assets | ||||||||||||||
| Investments & Other | 39,687,592 | 41,270,455 | 42,054,127 | 39,692,014 | 36,664,984 | 35,797,823 | 38,998,624 | 33,128,597 | 32,937,686 | 31,516,143 | 30,860,955 | 28,147,812 | 27,744,655 | 23,163,835 |
| Debtors (Due After 1 year) | ||||||||||||||
| Total Fixed Assets | 46,233,247 | 48,054,880 | 47,576,878 | 45,507,173 | 42,544,995 | 41,835,909 | 44,977,799 | 38,223,383 | 36,811,296 | 35,964,467 | 33,805,210 | 31,235,033 | 30,469,988 | 25,734,190 |
| Stock & work in progress | ||||||||||||||
| Trade Debtors | 441,345 | 724,877 | 728,883 | 691,617 | 214,422 | 306,203 | 354,093 | 203,722 | 123,208 | 7,404 | 156,250 | 473,001 | ||
| Group Debtors | ||||||||||||||
| Misc Debtors | 1,449,165 | 406,692 | 110,068 | 446,606 | 488,806 | 74,057 | 672,370 | 5,889,834 | 72,969 | 196,357 | 44,749 | 40,399 | 65,690 | 6,008 |
| Cash | 3,753,288 | 4,602,205 | 4,527,337 | 3,774,281 | 6,930,005 | 4,079,099 | 2,494,300 | 2,371,931 | 1,774,808 | 1,297,335 | 1,037,721 | 1,377,207 | 161,454 | 392,263 |
| misc current assets | 3,568,532 | |||||||||||||
| total current assets | 5,643,798 | 5,733,774 | 5,366,288 | 4,912,504 | 7,633,233 | 8,027,891 | 3,520,763 | 8,465,487 | 1,970,985 | 1,501,096 | 1,082,470 | 1,573,856 | 227,144 | 871,272 |
| total assets | 51,877,045 | 53,788,654 | 52,943,166 | 50,419,677 | 50,178,228 | 49,863,800 | 48,498,562 | 46,688,870 | 38,782,281 | 37,465,563 | 34,887,680 | 32,808,889 | 30,697,132 | 26,605,462 |
| Bank overdraft | ||||||||||||||
| Bank loan | ||||||||||||||
| Trade Creditors | 89,348 | 49,304 | 112,665 | 173,581 | 74,320 | 234,604 | 217,100 | 1,034,492 | 120,682 | 58,553 | 125,504 | 182,808 | 94,726 | |
| Group/Directors Accounts | ||||||||||||||
| other short term finances | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| other current liabilities | 926,712 | 1,097,320 | 919,545 | 917,618 | 579,704 | 771,096 | 784,217 | 1,730,910 | 556,062 | 164,127 | 127,098 | 268,126 | 83,536 | 496,153 |
| total current liabilities | 1,016,060 | 1,146,624 | 1,032,210 | 1,091,199 | 654,024 | 1,005,700 | 1,001,317 | 2,765,402 | 676,744 | 222,680 | 252,602 | 450,934 | 178,262 | 496,153 |
| loans | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| Accruals and Deferred Income | ||||||||||||||
| other liabilities | ||||||||||||||
| provisions | ||||||||||||||
| total long term liabilities | ||||||||||||||
| total liabilities | 1,016,060 | 1,146,624 | 1,032,210 | 1,091,199 | 654,024 | 1,005,700 | 1,001,317 | 2,765,402 | 676,744 | 222,680 | 252,602 | 450,934 | 178,262 | 496,153 |
| net assets | 50,860,985 | 52,642,030 | 51,910,956 | 49,328,478 | 49,524,204 | 48,858,100 | 47,497,245 | 43,923,468 | 38,105,537 | 37,242,883 | 34,635,078 | 32,357,955 | 30,518,870 | 26,109,309 |
| total shareholders funds | 50,860,985 | 52,642,030 | 51,910,956 | 49,328,478 | 49,524,204 | 48,858,100 | 47,497,245 | 43,923,468 | 38,105,537 | 37,242,883 | 34,635,078 | 32,357,955 | 30,518,870 | 26,109,309 |
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | ||||||||||||||
| Depreciation | 300,988 | 350,237 | 312,669 | 268,811 | 248,818 | 217,341 | 162,386 | 137,237 | 137,237 | 176,447 | 154,264 | 140,775 | 128,458 | 136,153 |
| Amortisation | ||||||||||||||
| Tax | ||||||||||||||
| Stock | ||||||||||||||
| Debtors | 758,941 | 292,618 | -299,272 | 434,995 | 322,968 | -646,203 | -5,067,093 | 5,897,379 | -7,584 | 159,012 | -151,900 | 130,959 | -413,319 | 479,009 |
| Creditors | 40,044 | -63,361 | -60,916 | 99,261 | -160,284 | 17,504 | -817,392 | 913,810 | 62,129 | -66,951 | -57,304 | 88,082 | 94,726 | |
| Accruals and Deferred Income | -170,608 | 177,775 | 1,927 | 337,914 | -191,392 | -13,121 | -946,693 | 1,174,848 | 391,935 | 37,029 | -141,028 | 184,590 | -412,617 | 496,153 |
| Deferred Taxes & Provisions | ||||||||||||||
| Cash flow from operations | ||||||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | 15,768 | -6,235,179 | 3,486,078 | -357,526 | ||||||||||
| Change in Investments | -1,582,863 | -783,672 | 2,362,113 | 3,027,030 | 867,161 | -3,200,801 | 5,870,027 | 190,911 | 1,421,543 | 655,188 | 2,713,143 | 403,157 | 4,580,820 | 23,163,835 |
| cash flow from investments | 1,582,863 | 783,672 | -2,362,113 | -3,027,030 | -867,161 | 3,216,569 | -12,105,206 | 3,295,167 | -1,779,069 | |||||
| Financing Activities | ||||||||||||||
| Bank loans | ||||||||||||||
| Group/Directors Accounts | ||||||||||||||
| Other Short Term Loans | ||||||||||||||
| Long term loans | ||||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||||
| other long term liabilities | ||||||||||||||
| share issue | ||||||||||||||
| interest | ||||||||||||||
| cash flow from financing | -1,547,017 | 789,725 | 2,400,621 | -813,934 | -326,934 | 516,183 | 1,265,623 | 5,325,270 | 433,901 | 1,810,739 | 2,079,211 | -1,372,574 | 4,463,084 | 25,445,992 |
| cash and cash equivalents | ||||||||||||||
| cash | -848,917 | 74,868 | 753,056 | -3,155,724 | 2,850,906 | 1,584,799 | 122,369 | 597,123 | 477,473 | 259,614 | -339,486 | 1,215,753 | -230,809 | 392,263 |
| overdraft | ||||||||||||||
| change in cash | -848,917 | 74,868 | 753,056 | -3,155,724 | 2,850,906 | 1,584,799 | 122,369 | 597,123 | 477,473 | 259,614 | -339,486 | 1,215,753 | -230,809 | 392,263 |
the foundation for liver research Credit Report and Business Information
The Foundation For Liver Research Competitor Analysis
Perform a competitor analysis for the foundation for liver research by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in SE5 area or any other competitors across 12 key performance metrics.
the foundation for liver research Ownership
THE FOUNDATION FOR LIVER RESEARCH group structure
The Foundation For Liver Research has 1 subsidiary company.
Ultimate parent company
THE FOUNDATION FOR LIVER RESEARCH
07156633
1 subsidiary
the foundation for liver research directors
The Foundation For Liver Research currently has 9 directors. The longest serving directors include Colonel Hamon Massey (Feb 2010) and Sir Jeremy Elwes (Feb 2010).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Colonel Hamon Massey | England | 74 years | Feb 2010 | - | Director |
| Sir Jeremy Elwes | 87 years | Feb 2010 | - | Director | |
| Professor Alan McGregor | England | 76 years | Jun 2017 | - | Director |
| Professor Sir Ian Gilmore | England | 78 years | Jun 2019 | - | Director |
| Mr Simon Wainwright | 67 years | Apr 2020 | - | Director | |
| Mr Charles Hopkinson-Woolley | England | 60 years | Feb 2022 | - | Director |
| Professor Rebecca Fitzgerald | England | 56 years | Sep 2022 | - | Director |
| Professor Christopher Day | England | 65 years | Oct 2022 | - | Director |
| Mrs Anna Bennett | England | 47 years | Nov 2024 | - | Director |
P&L
June 2023turnover
3m
+9%
operating profit
-442.9k
0%
gross margin
54.7%
+6.39%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2023net assets
50.9m
-0.03%
total assets
51.9m
-0.04%
cash
3.8m
-0.18%
net assets
Total assets minus all liabilities
the foundation for liver research company details
company number
07156633
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
72110 - Research and experimental development on biotechnology
incorporation date
February 2010
age
15
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
June 2023
previous names
N/A
accountant
-
auditor
CATON FRY & CO LIMITED
address
111 coldharbour lane, london, SE5 9NT
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
PITMANS LLP
the foundation for liver research Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to the foundation for liver research.
the foundation for liver research Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for THE FOUNDATION FOR LIVER RESEARCH. This can take several minutes, an email will notify you when this has completed.
the foundation for liver research Companies House Filings - See Documents
| date | description | view/download |
|---|
